Key Takeaways
- CES 2024 was dominated by AI announcements, with NVIDIA unveiling new chips and AI models for autonomous vehicles.
- NVIDIA acquired AI startup Grok for $20 billion, focusing on talent acquisition to improve AI inference.
- Novo Nordisk launched the first GLP-1 oral pill for obesity, priced significantly lower than injectable options.
- The GLP-1 market is projected to exceed $100 billion, with oral versions addressing common adoption barriers.
Deep Dive
- The Consumer Electronics Show (CES) in Las Vegas featured NVIDIA dominating headlines with its new 'Rubin' chip in full production.
- NVIDIA CEO Jensen Huang introduced AI models for autonomous vehicles, stating the 'chat GPT moment for physical AI is here.'
- Alex Heath noted CES has evolved from hardware showcases to an event primarily for international companies and startups, often featuring unproven products.
- The overarching theme at CES appeared to be AI, with a focus on wearables, voice-activated rings, AI glasses, and robotics.
- Many robotics demonstrations were considered 'vaporware' until seen in real-world application, despite optimism for a 'ChatGPT moment for physical AI.'
- Lenovo, the world's largest PC maker, announced new AI product offerings for its PCs, integrating multiple AIs for a more natural, context-aware experience.
- NVIDIA reportedly acquired chip startup Grok for $20 billion in a 'reverse Aqua Hire' deal to gain key talent rather than just technology.
- The acquisition aims to address issues with AI inference latency on NVIDIA GPUs, indicating a strategic move for talent acquisition.
- The deal was executed rapidly, within days, suggesting NVIDIA's strong focus on improving its AI inference capabilities.
- Novo Nordisk launched the first GLP-1 pill for obesity treatment, priced between $149-$299 per month, significantly lower than injectable options.
- This development aims to reach over 100 million Americans with obesity, broadening patient access to treatment.
- Following the announcement, Novo Nordisk’s stock experienced a 5% increase.
- The new oral GLP-1 medication's monthly price range of $149 to $299 is significantly lower than injectables, enhancing patient access.
- This pricing strategy is seen as crucial for individuals paying out-of-pocket, potentially making it more accessible than some gym memberships for weight loss.
- Jared Holz noted the broader GLP-1 market's potential to exceed $100 billion, with oral versions expected to capture a significant share despite past efficacy data showing variability.
- Despite theories of reaching 'peak GLP-1,' over 40 million Americans currently use these drugs, with the industry's story viewed as just beginning.
- The introduction of Novo Nordisk's new Wegovy pill addresses needle phobia, which affects 63% of adults and is a significant barrier to injectable treatments.
- Eli Lilly and Chinese companies are also developing similar GLP-1 pills, indicating a competitive and expanding market for oral obesity treatments.